These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 28453189)
1. Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: A focused update. Patel P; Robinson PD; Thackray J; Flank J; Holdsworth MT; Gibson P; Orsey A; Portwine C; Freedman J; Madden JR; Phillips R; Sung L; Dupuis LL Pediatr Blood Cancer; 2017 Oct; 64(10):. PubMed ID: 28453189 [TBL] [Abstract][Full Text] [Related]
2. Palonosetron: in the prevention of nausea and vomiting. Yang LP; Scott LJ Drugs; 2009 Nov; 69(16):2257-78. PubMed ID: 19852528 [TBL] [Abstract][Full Text] [Related]
3. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Rubenstein EB Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194 [TBL] [Abstract][Full Text] [Related]
4. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415 [TBL] [Abstract][Full Text] [Related]
5. Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting. Balu S; Buchner D; Craver C; Gayle J Clin Ther; 2011 Apr; 33(4):443-55. PubMed ID: 21635990 [TBL] [Abstract][Full Text] [Related]
6. Palonosetron for the prevention of chemotherapy-induced nausea and vomiting. Mori-Vogt S; Blazer M Expert Rev Anticancer Ther; 2013 Aug; 13(8):919-36. PubMed ID: 23984894 [TBL] [Abstract][Full Text] [Related]
7. Palonosetron versus other 5-HT₃ receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies treated with emetogenic chemotherapy in a hospital outpatient setting in the United States. Craver C; Gayle J; Balu S; Buchner D J Med Econ; 2011; 14(3):341-9. PubMed ID: 21542674 [TBL] [Abstract][Full Text] [Related]
8. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting. Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119 [TBL] [Abstract][Full Text] [Related]
12. A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). Zhang L; Lu S; Feng J; Dechaphunkul A; Chang J; Wang D; Chessari S; Lanzarotti C; Jordan K; Aapro M Ann Oncol; 2018 Feb; 29(2):452-458. PubMed ID: 29092012 [TBL] [Abstract][Full Text] [Related]
14. Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study. Kovács G; Wachtel AE; Basharova EV; Spinelli T; Nicolas P; Kabickova E Lancet Oncol; 2016 Mar; 17(3):332-344. PubMed ID: 26795844 [TBL] [Abstract][Full Text] [Related]
15. Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist. Navari RM Expert Opin Drug Metab Toxicol; 2009 Dec; 5(12):1577-86. PubMed ID: 19929251 [TBL] [Abstract][Full Text] [Related]
16. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents. Navari RM J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652 [TBL] [Abstract][Full Text] [Related]
17. New antiemetic drugs. Roila F; Fatigoni S Ann Oncol; 2006 Mar; 17 Suppl 2():ii96-100. PubMed ID: 16608997 [TBL] [Abstract][Full Text] [Related]
18. Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: comparison between elderly and non-elderly patient response. Massa E; Astara G; Madeddu C; Dessì M; Loi C; Lepori S; Mantovani G Crit Rev Oncol Hematol; 2009 Apr; 70(1):83-91. PubMed ID: 18723369 [TBL] [Abstract][Full Text] [Related]
19. The current status of the use of palonosetron. Navari R Expert Opin Pharmacother; 2013 Jul; 14(10):1281-4. PubMed ID: 23647207 [TBL] [Abstract][Full Text] [Related]
20. Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting. Hajdenberg J; Grote T; Yee L; Arevalo-Araujo R; Latimer LA J Support Oncol; 2006 Oct; 4(9):467-71. PubMed ID: 17080735 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]